Individual components: BPC-157 5mg Body Protection Compound for comprehensive healing TB500 5mg Thymosin Beta-4 for cellular migration and recovery Complementary healing peptides: GHK-Cu 50mg Copper peptide for tissue remodeling and anti-aging Thymosin Alpha-1 10mg Immune support and recovery Growth hormone support: Ipamorelin 5mg Growth hormone secretagogue for recovery CJC-1295 DAC 5mg Long-acting GH releaser IGF-1 LR3 1mg Insulin-like growth factor for muscle recovery Essential supplies: Sterile Water 3ml For proper reconstitution Peptide Calculator For accurate dosing Research resources: Shop All Peptides Complete collection Healing & Recovery Peptides Specialized compounds Technical Specifications Product name: BPC-157 5mg + TB500 5mg Blend Composition: BPC-157: 5mg (pentadecapeptide, 15 amino acids) TB500: 5mg (43-amino-acid peptide) Total peptide content: 10mg per vial Purity: 99% (verified by HPLC) Form: Freeze-dried powder Storage: Unreconstituted: 28C (refrigerated) or -20C (frozen) Reconstituted: 28C (refrigerated), use within 1428 days Reconstitution: Sterile water (0.9% benzyl alcohol) Routes: Subcutaneous or intramuscular injection Typical dosing: 250500mcg of each peptide, once or twice daily Research uses: Tissue healing and repair Inflammation and chronic inflammation research Post-surgical recovery Chronic injury research Sports medicine research Regenerative medicine studies Quality assurance: Third-party tested for purity and potency Manufactured in the USA following GMP standards Certificate of Analysis included with each order Sterile, pharmaceutical-grade production Regulatory status: For research purposes only, not for human consumption
Chronic Toxicity and Carcinogenicity Studies of the Long-Acting GLP-1 Receptor Agonist Dulaglutide in Rodents (Endocrinology)
Boost your glutathione precursors by eating sulfur-rich vegetables like broccoli, garlic, and onions
A deficiency of CD4+CD25+ T cells permits the development of spontaneous lupus-like disease in mice, and can be reversed by induction of mucosal tolerance to histone peptide autoantigen
Previous studies have reported inconsistent results when comparing oral, sublingual, and intramuscular administration, often limited by small sample sizes or heterogeneous populations (Houle et al., 2014
Hepatology 70 , 276293 (2019)
